913P Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer

Autor: Redondo González, J.C., Olivares Hernandez, A., Garcia Hernandez, J.L., Mesia Nin, R., Rubio Casadevall, J., Garcia Giron, C., Iglesias Docampo, L., Carral Maseda, A., Taberna Sanz, M., Vázquez Fernández, S., Corchete Sánchez, L.A., Gestoso Uzal, N., González Sarmiento, R., Fonseca Sánchez, E., Cruz Hernandez, J.J., del Barco Morillo, E.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S642-S642

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study

Autor: Martínez-Trufero J, Lozano Borbalas A, Pajares Bernad I, Taberna Sanz M, Ortega Izquierdo E, Cirauqui Cirauqui B, Rubió-Casadevall J, Plana Serrahima M, Ponce Ortega JM, Planas Toledano I, Caballero J, Marruecos Querol J, Iglesias Docampo L, Lambea Sorrosal J, Adansa JC, Mesía Nin R

Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Sequential treatment of Panitumumab (Pb) plus Paclitaxel (Px) as induction treatment (IT) followed by concurrent bioradiotherapy (Bio-RT) with Pb may be an alternative for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) in pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1d9125ed82c20f67ebaaf32b3723807d
https://pubmed.ncbi.nlm.nih.gov/33876416

701P Genomic alteration relationships with toxicity to TPF induction chemotherapy in head and neck squamous cell carcinoma patients participating in a clinical trial

Autor: Olivares Hernandez, A., García, J.L., Alonso, N., Corchete Sánchez, L.A., Perez García, J., Mesia Nin, R., Rubió-Casadevall, J., Garcia Giron, C., Iglesias Docampo, L., Carral Maseda, A., Taberna Sanz, M., Vazquez, S., Gómez Muñoz, A., del Barco, E., González Sarmiento, R., Cruz Hernandez, J.J.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S862-S863

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy.

Autor: Marín-Jiménez JA; Head and Neck Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain., Oliva M; Head and Neck Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain.; Oncobell Program - Bellvitge Biomedical Research Institute (Institut d'Investigació Biomèdica de Bellvitge), Barcelona, Spain., Peinado Martín P; Head and Neck Cancer Unit, Department of Medical Oncology, Hospital Universitario Clínico San Carlos - Instituto de Investigación Sanitaria Hospital Clínica San Carlos, Madrid, Spain., Cabezas-Camarero S; Head and Neck Cancer Unit, Department of Medical Oncology, Hospital Universitario Clínico San Carlos - Instituto de Investigación Sanitaria Hospital Clínica San Carlos, Madrid, Spain., Plana Serrahima M; Head and Neck Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain., Vázquez Masedo G; Department of Radiation Oncology, Hospital Universitario Clínico San Carlos - Instituto de Investigación Sanitaria Hospital Clínica San Carlos (IdISCC), Madrid, Spain., Lozano Borbalas A; Department of Radiation Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain., Cabrera Martín MN; Department of Nuclear Medicine, Hospital Universitario Clínico San Carlos - IdISCC, Madrid, Spain., Esteve A; Department of Medical Oncology, Catalan Institute of Oncology (ICO-Badalona), B-ARGO group, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Barcelona, Spain.; Oncology Data Analytics Program, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat) - Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain., Iglesias Moreno MC; Otolaryngology - Head and Neck Surgery Department, Hospital Universitario Clínico San Carlos e- IdISCC, Madrid, Spain., Vilajosana Altamis E; Head and Neck Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain., Arribas Hortigüela L; Clinical Nutrition Unit, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain., Taberna Sanz M; Head and Neck Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain.; Oncobell Program - Bellvitge Biomedical Research Institute (Institut d'Investigació Biomèdica de Bellvitge), Barcelona, Spain., Pérez-Segura P; Head and Neck Cancer Unit, Department of Medical Oncology, Hospital Universitario Clínico San Carlos - Instituto de Investigación Sanitaria Hospital Clínica San Carlos, Madrid, Spain., Mesía R; Department of Medical Oncology, Catalan Institute of Oncology (ICO-Badalona), B-ARGO group, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Barcelona, Spain.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Jul 22; Vol. 12, pp. 953020. Date of Electronic Publication: 2022 Jul 22 (Print Publication: 2022).